UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

BCL-2 family isoforms in apoptosis and cancer

Cell death & disease, 2019-02, Vol.10 (3), p.177-177, Article 177

2019

Link zum Volltext

Verfügbarkeit prüfen

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

Nature reviews. Cancer, 2016-02, Vol.16 (2), p.99

2016

Link zum Volltext

Verfügbarkeit prüfen

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

Cell stem cell, 2013-03, Vol.12 (3), p.329-341

2013

Link zum Volltext

Verfügbarkeit prüfen

The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update

Archives of toxicology, 2015-03, Vol.89 (3), p.289-317

2015

Link zum Volltext

Verfügbarkeit prüfen

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

Molecular cell, 2016-11, Vol.64 (3), p.493-506

2016

Link zum Volltext

Verfügbarkeit prüfen

BCL2 and MCL1 inhibitors for hematologic malignancies

Blood, 2021-09, Vol.138 (13), p.1120-1136

2021

Link zum Volltext

Verfügbarkeit prüfen

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Nature communications, 2019-06, Vol.10 (1), p.2385-2385, Article 2385

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes

Cell metabolism, 2019-05, Vol.29 (5), p.1045-1060.e10

2019

Link zum Volltext

Verfügbarkeit prüfen

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia

Cancer discovery, 2018-12, Vol.8 (12), p.1566-1581

2018

Link zum Volltext

Verfügbarkeit prüfen

BCL2 and miR-15/16: from gene discovery to treatment

Cell death and differentiation, 2018-01, Vol.25 (1), p.21-26

2018

Link zum Volltext

Verfügbarkeit prüfen

BCL-2 inhibition in AML: an unexpected bonus?

Blood, 2018-09, Vol.132 (10), p.1007-1012

2018

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

Nature medicine, 2018-12, Vol.24 (12), p.1859-1866

2018

Link zum Volltext

Verfügbarkeit prüfen

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Cancer cell, 2019-10, Vol.36 (4), p.369-384.e13

2019

Link zum Volltext

Verfügbarkeit prüfen

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Nature reviews. Drug discovery, 2017-04, Vol.16 (4), p.273-284

2017

Link zum Volltext

Verfügbarkeit prüfen

Pathways and mechanisms of venetoclax resistance

Leukemia & lymphoma, 2017-09, Vol.58 (9), p.2026-2039

2017

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

The lancet oncology, 2018-01, Vol.19 (1), p.65-75

2018

Link zum Volltext

Verfügbarkeit prüfen

A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics

Biochemical pharmacology, 2019-04, Vol.162, p.250-261

2019

Link zum Volltext

Verfügbarkeit prüfen

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

Clinical cancer research, 2012-05, Vol.18 (9), p.2502-2514

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Nature communications, 2017-07, Vol.8 (1), p.16078-16078, Article 16078

2017

Link zum Volltext

Verfügbarkeit prüfen

Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death

Molecular cell, 2015-03, Vol.57 (5), p.860-872

2015

Link zum Volltext

Verfügbarkeit prüfen

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

Molecular cancer therapeutics, 2016-09, Vol.15 (9), p.2011-2017

2016

Link zum Volltext

Verfügbarkeit prüfen

The rise of apoptosis: targeting apoptosis in hematologic malignancies

Blood, 2018-09, Vol.132 (12), p.1248-1264

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 4.794

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.529)
Mit Volltextzugriff
(4.379)

Publikationsform

Artikel
(4.791)
Buchkapitel
(3)

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(4.176)
Life Sciences & Biomedicine
(3.991)
Humans
(3.682)
Proto-Oncogene Proteins C-Bcl-2 - Metabolism
(2.832)
Apoptosis
(2.575)
Apoptosis - Drug Effects
(2.474)
Animals
(2.175)
Proto-Oncogene Proteins C-Bcl-2 - Antagonists & Inhibitors
(1.718)
Oncology
(1.469)
Proto-Oncogene Proteins C-Bcl-2 - Genetics
(1.469)
Cell Line, Tumor
(1.401)
Mice
(1.249)
Cell Biology
(1.138)
Biological And Medical Sciences
(1.045)
Biochemistry & Molecular Biology
(996)
Antineoplastic Agents - Pharmacology
(892)
Male
(861)
Medical Sciences
(827)
Female
(796)
Proteins
(724)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(143)
Oncogene
(142)
The Journal Of Biological Chemistry
(128)
Blood
(118)
Biochemical And Biophysical Research Communications
(97)
Plos One
(97)
Cell Death And Differentiation
(87)
Molecular Cancer Therapeutics
(86)
The Journal Of Immunology
(85)
Clinical Cancer Research
(81)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BCL-2 family isoforms in apoptosis and cancer

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

BCL2 and MCL1 inhibitors for hematologic malignancies

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia

BCL2 and miR-15/16: from gene discovery to treatment

BCL-2 inhibition in AML: an unexpected bonus?

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Pathways and mechanisms of venetoclax resistance

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

The rise of apoptosis: targeting apoptosis in hematologic malignancies

Suchergebnisse filtern